Atommap

Atommap Corp, which rebranded as Fathom Therapeutics in April 2026, is a New York-based drug design company using quantum chemistry and AI to model protein behavior at atomic resolution. Its Microcosmos engine simulates protein motion and protein-ligand interactions to generate the dynamic structural data needed to design small molecules against targets conventionally considered undruggable. The company runs internal discovery programs alongside partnered discovery collaborations, and maintains a second office in Boston. It was founded in 2023 by CEO Huafeng Xu with CTO Yujie Wu and Chief Computational Scientist Jesus Izaguirre.

Proprietary simulation algorithms that accelerate atomic-resolution modeling of protein dynamics by roughly 10,000x without sacrificing accuracy, letting the team design molecules that modulate protein behavior rather than only bind static structures -- in one reported case producing potent degrader candidates against an undruggable target in six weeks.